SCHEMBL1969512

SCHEMBL1969512

O=C1NCCO1.[LiH]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL969300 0.97
SCHEMBL4198 0.97
Fluoride SCHEMBL27461973 0.97
SCHEMBL4621927 0.97 FABP6 (0.35)
SCHEMBL80643 0.97
SCHEMBL7117843 0.94
Iodide SCHEMBL7938108 0.94
Hydrochloric Acid SCHEMBL1061350 0.94
Hydrochloric Acid SCHEMBL2080171 0.94
SCHEMBL6678827 0.94

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114591272-B Preparation method of intermediate compound used for synthesizing posaconazole and intermediate compound prepared by same 浙江奥翔药业股份有限公司 2024-04-05 CN disclosed
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
WO-2023173717-A1 PREPARATION METHOD FOR INTERMEDIATE COMPOUND ACTING AS SYNTHETIC POSACONAZOLE, AND INTERMEDIATE COMPOUND PREPARED THEREBY 浙江奥翔药业股份有限公司 2023-09-21 WO disclosed
CN-115448911-A Preparation method of posaconazole intermediate 成都海博为药业有限公司 2022-12-09 CN disclosed
CN-114591272-A Preparation method of intermediate compound for synthesizing posaconazole and intermediate compound prepared by same 浙江奥翔药业股份有限公司 2022-06-07 CN disclosed
US-RE48334-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-12-01 US disclosed
WO-2019077627-A1 A PROCESS FOR THE MANUFACTURE OF POSACONAZOLE METROCHEM API PVT LTD. (IN) 2019-04-25 WO disclosed
US-10266560-B2 Bile acid analogs as FXR/TGR5 agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2019-04-23 US disclosed
EP-2758385-B1 PROCESS FOR THE PREPARATION OF TRIAZOLE ANTIFUNGAL DRUG, ITS INTERMEDIATES AND POLYMORPHS THEREOF MSN LAB LTD (IN) 2018-03-28 EP disclosed
EP-3215179-A1 BILE ACID ANALOGS AN FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF Enanta Pharmaceuticals, Inc. (US) 2017-09-13 EP disclosed
EP-0934305-A4 INTEGRIN ANTAGONISTS MERCK & CO INC (US) 2001-04-11 EP disclosed
US-6211184-B1 TETRAHYDRO-PYRAZINE OR PYRIMIDINE DERIVATIVES; VITRONECTIN RECEPTOR ANTAGONIST; OSTEOPOROSIS; ANTIINFLAMMATORY, ANTITUMOR AGENTS; ANGIOGENESIS AND RESTENOSIS INHIBITORS MERCK & CO., INC. 2001-04-03 US disclosed
EP-0973396-A4 A METHOD OF TREATING CANCER MERCK & CO INC (US) 2001-02-07 EP disclosed
EP-0973396-A1 A METHOD OF TREATING CANCER Merck & Co., Inc. (US) 2000-01-26 EP disclosed
US-5981546-A Integrin antagonists MERCK & CO., INC. (US) 1999-11-09 US disclosed
EP-0934305-A1 INTEGRIN ANTAGONISTS Merck & Co., Inc. (US) 1999-08-11 EP disclosed
WO-1998046220-A1 COMBINATION THERAPY FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS MERCK & CO., INC. (US) 1998-10-22 WO disclosed
WO-1998044797-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1998-10-15 WO disclosed
WO-1998008840-A1 INTEGRIN ANTAGONISTS MERCK & CO., INC. (US) 1998-03-05 WO disclosed
WO-1994006291-A1 SOLID PHASE AND COMBINATORIAL SYNTHESIS OF COMPOUNDS ON A SOLID SUPPORT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1994-03-31 WO disclosed